Study identifier:D9617C00003
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Efficacy of esomeprazole 40 mg once daily versus placebo and esomeprazole 20 mg once daily versus placebo in treatment for relief of upper gastrointestinal symptoms associated with continuous use of NSAIDs including COX-2 selective NSAIDs
NSAIDs
Phase 3
No
Esomeprazole
All
556
Interventional
18 Years +
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Jan 2011 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|